### ðŸ«  Dyslipidemia: High-Intensity Statin Therapy in ASCVD

#### âœ… True Statements
1. **High-intensity statin therapy** with either **atorvastatin** or **rosuvastatin** is standard of care for patients with **atherosclerotic cardiovascular disease (ASCVD)**, including **prior myocardial infarction**.
2. **Presence of ASCVD alone**â€”including **coronary**, **cerebrovascular**, or **peripheral arterial disease**â€”is sufficient to initiate **statin therapy**, regardless of **low-density lipoprotein (LDL) cholesterol** level.
3. In **secondary prevention** of ASCVD, the **goal of statin therapy** is a **â‰¥50% reduction in LDL cholesterol** and an **LDL level <70 mg/dL (1.8 mmol/L)**.
4. **Ezetimibe** should be added to **maximally tolerated statin therapy** in ASCVD patients if there is **<50% LDL reduction** or **LDL â‰¥70 mg/dL (1.8 mmol/L)**.
5. In **very high-risk ASCVD patients**â€”defined as having **multiple major ASCVD events** or **one event plus multiple risk factors**â€”the goal **LDL level is <55 mg/dL (1.4 mmol/L)**.
6. **High-sensitivity C-reactive protein (hs-CRP)** testing is used to guide **initial statin therapy** in borderline-risk patients, but not in those with **established ASCVD**.
7. **Rosuvastatin** and **atorvastatin** are both appropriate high-intensity statins, and switching between them is not necessary if LDL goals are achieved.

#### ðŸ’¬ Extra
1. This patient's **LDL cholesterol dropped by more than 50%** with **high-dose rosuvastatin**, indicating appropriate secondary prevention.
4. Nonstatin agents like **ezetimibe** are reserved for patients not meeting **LDL targets** despite **maximally tolerated statin therapy**.
5. This patient lacks **very high-risk features**, such as multiple ASCVD events or multiple comorbidities, so the **<55 mg/dL goal** does not apply.
6. **hs-CRP â‰¥0.2 mg/dL (2.0 mg/L)** can aid in **primary prevention risk discussions**, not required in **secondary prevention**.
7. Both statins are considered **equivalent options** for ASCVD when dosed at high intensity.

#### ðŸ”· Tags
#Cardiology #Dyslipidemia #AmbulatoryCare #HighValueCare

#### ðŸ“™ Reference
Virani SS, Newby LK, Arnold SV, et al; Writing Committee Members. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2023;82:833-955. PMID: 37480922 doi:10.1016/j.jacc.2023.04.003

#### ðŸ†” Question ID
CVMCQ24027

#### ðŸ•’ Last Updated
February 2025

---

#### ðŸ“– Related Text
MKSAP 19: Cardiovascular Medicine â€” Dyslipidemia, Secondary Prevention of Atherosclerotic Cardiovascular Disease

---

### ðŸ“˜ Related Text Derivations

#### âœ… True Statements
1. **Secondary prevention statin therapy** is appropriate for patients with **acute coronary syndrome**, **myocardial infarction**, **angina**, **coronary revascularization**, **stroke**, **transient ischemic attack**, **peripheral artery disease**, or **aortic aneurysm**.
2. **High-intensity statin therapy** should be initiated in ASCVD patients **aged â‰¤75 years** to achieve **â‰¥50% LDL reduction**.
3. If **high-intensity statin therapy** is not tolerated, **moderate-intensity statins** should be used to achieve **30â€“49% LDL reduction**.
4. If LDL goals are not met with statins alone, **ezetimibe** is the **first-line nonstatin** to add.
5. If further LDL reduction is needed, **PCSK9 monoclonal antibodies** may be considered, especially now that their **cost-effectiveness** has improved.
6. **Very high-risk ASCVD patients** may require **ezetimibe and/or PCSK9 inhibitors** if LDL remains above **55 mg/dL (1.4 mmol/L)** despite maximal statin therapy.
7. The **American Diabetes Association (ADA)** recommends **high-intensity statins** for all patients with **diabetes and ASCVD**, with escalation to **ezetimibe or PCSK9 inhibitors** as needed.
8. The **VA/DoD cholesterol guidelines** recommend **at least moderate-intensity statins** in all ASCVD patients, and **high-intensity therapy** in those at higher risk.

#### ðŸ’¬ Extra
1. These conditions define the population eligible for **secondary prevention** lipid-lowering therapy.
2. The **<75 age threshold** aligns with trial inclusion criteria and balances benefit vs. tolerability.
5. **PCSK9 inhibitors** are now **more accessible** due to cost reductions, increasing their use in refractory hyperlipidemia.
7. The ADA aligns with ACC/AHA in using **LDL response thresholds** to guide therapy.
8. Higher-risk patients in VA/DoD include those with **recent MI/ACS**, **stroke recurrence**, or **CVD with other risk factors**.

#### ðŸ”· Tags
#Dyslipidemia #SecondaryPrevention #StatinTherapy #PCSK9Inhibitors #DiabetesCare #LDLTargets

---

#### ðŸ—¾ Supplemental Table

<table>
  <caption><strong>Summary of the U.S. Department of Veterans Affairs/U.S. Department of Defense Dyslipidemia Pharmacotherapy Recommendations</strong></caption>
  <thead>
    <tr>
      <th>Recommendation Topic</th>
      <th>Conclusion</th>
    </tr>
  </thead>
  <tbody>
    <tr><td colspan="2"><strong>Primary Prevention</strong></td></tr>
    <tr><td>Moderate-intensity statin therapy for patients with a 10-year CVD risk â‰¥12%, an LDL cholesterol level â‰¥190 mg/dL (4.92 mmol/L), or diabetes mellitus</td><td>Recommended</td></tr>
    <tr><td>Moderate-intensity statin therapy for patients with a 10-year CVD risk between 6% and 12%</td><td>Suggested if patient prefers treatment</td></tr>
    <tr><td>PCSK9 inhibitors</td><td>Recommended against</td></tr>
    <tr><td>Ezetimibe</td><td>No recommendation</td></tr>

    <tr><td colspan="2"><strong>Secondary Prevention</strong></td></tr>
    <tr><td>At least moderate-intensity statin therapy</td><td>Recommended</td></tr>
    <tr><td>High-intensity statin therapy for higher-risk patients<sup>a,b</sup></td><td>Suggested</td></tr>
    <tr><td>Adding ezetimibe to statin therapy for higher-risk patients<sup>a,b</sup></td><td>Suggested</td></tr>
    <tr><td>PCSK9 inhibitor for higher-risk patients<sup>b,c</sup></td><td>Suggested</td></tr>

    <tr><td colspan="2"><strong>Other Medications, Supplements, and Nutraceuticals</strong></td></tr>
    <tr><td>Adding icosapent ethyl to statin therapy for secondary prevention in patients with persistently elevated fasting triglyceride levels >150 mg/dL (1.69 mmol/L)</td><td>Suggested</td></tr>
    <tr><td>Niacin for primary or secondary prevention</td><td>Recommended against</td></tr>
    <tr><td>Adding fibrates to statin therapy for primary or secondary prevention</td><td>Suggested against</td></tr>
    <tr><td>Omega-3 fatty acids as dietary supplements for primary or secondary prevention</td><td>Suggested against</td></tr>
    <tr><td>Adding icosapent ethyl to statin therapy for primary prevention in patients with persistently elevated fasting triglyceride levels >150 mg/dL (1.69 mmol/L)</td><td>No recommendation</td></tr>

    <tr><td colspan="2"><strong>Monitoring</strong></td></tr>
    <tr><td>Routine monitoring of lipid levels in patients receiving statin therapy</td><td>Suggested against</td></tr>
  </tbody>
</table>

<p><em>
CVD = cardiovascular disease; PCSK9 = proprotein convertase subtilisin/kexin type 9.<br>
<sup>a</sup> In patients who are willing to intensify treatment after discussing the risk of high-intensity statin therapy.<br>
<sup>b</sup> Higher-risk patients include those with a myocardial infarction or acute coronary syndrome in the past 12 months; recurrent acute coronary syndrome, myocardial infarction, or stroke; or established CVD with additional risk factors (e.g., currently smoking, diabetes, peripheral artery disease, or coronary revascularization).<br>
<sup>c</sup> In patients who are willing to intensify treatment after discussing the uncertain long-term safety and benefits.
</em></p>